ライフサイエンスコーパス: hairy cell

1 tigen that is strongly expressed by leukemic hairy cells.

2 1c promoter to levels equivalent to those in hairy cells.

3 hat it is sufficient to direct expression in hairy cells.

4 ith residual marrow disease (1% to 5% marrow hairy cells), and 2 (13%) had a partial response.

5 Hairy cells are clonal expansions of mature, activated B

6 Hairy cells are highly activated clonal B cells related

7 repared from other cell types indicated that hairy cells exhibit abnormal constitutive expression of

8 sent study was to address these issues using hairy cells (HCs) and chronic lymphocytic leukemia cells

9 ossible receptor-ligand interactions between hairy cells (HCs) and ECs were examined and a central im

10 Hairy cells (HCs) are mature malignant B cells that cont

11 One unusual feature of hairy cells (HCs) is the frequent expression of multiple

12 ellular signal-regulated kinase (ERK) in the hairy cells (HCs) of hairy cell leukemia.

13 The hairy cells (HCs) of hairy-cell leukemia are intrinsical

14 examine the effects of IFN-alpha on cultured hairy cells (HCs), taking into account the possible modi

15 ete response (CR), defined as presence of no hairy cells in BM and blood with normalization of counts

16 r signal-regulated kinase phosphorylation of hairy cells in vivo.

17 eukaemia is reviewed, focussing first on the hairy cell itself and then on its interactions with the

18 The biology of hairy-cell leukaemia is reviewed, focussing first on the

19 arge fraction of melanomas, thyroid cancers, hairy cell leukaemias and, to a smaller extent, a wide s

20 ia (29), T-cell prolymphocytic leukemia (3), hairy cell leukemia (1), adult T-cell leukemia/lymphoma

21 n bone marrow core biopsies of patients with hairy cell leukemia (HCL) after treatment with 2-chlorod

22 s, 28 low grade B-cell lymphomas, 4 cases of hairy cell leukemia (HCL) and 3 plasmacytomas.

23 V600E mutation was reported in all cases of hairy cell leukemia (HCL) but not in other peripheral B-

24 BRAFV600E mutation was recently detected in hairy cell leukemia (HCL) by whole exome sequencing.

25 tic leukemia (CLL) cases, 100% (32 of 32) of hairy cell leukemia (HCL) cases, 15% (5 of 34) of mantle

26 Hairy cell leukemia (HCL) derives from a mature B cell a

27 The discovery of effective therapy for hairy cell leukemia (HCL) has increased the relevance of

28 Hairy cell leukemia (HCL) is a chronic B-cell leukemia n

29 Hairy cell leukemia (HCL) is a chronic lymphoproliferati

30 Hairy cell leukemia (HCL) is a chronic mature B-cell neo

31 Hairy cell leukemia (HCL) is a distinct clinicopathologi

32 Hairy cell leukemia (HCL) is a distinct clinicopathologi

33 Hairy cell leukemia (HCL) is a rare, indolent B-cell dis

34 Hairy cell leukemia (HCL) is an indolent B-cell neoplasm

35 Hairy cell leukemia (HCL) is an uncommon, indolent, chro

36 Hairy cell leukemia (HCL) is characterized by underexpre

37 Cladribine treatment of hairy cell leukemia (HCL) is complicated by neutropenic

38 Hairy cell leukemia (HCL) is marked by near 100% mutatio

39 One hairy cell leukemia (HCL) patient achieved a complete re

40 Hairy cell leukemia (HCL) shows unique clinicopathologic

41 iral oncogene homolog B1 (BRAF) mutations in hairy cell leukemia (HCL) subsets, demonstrating that BR

42 To compare hairy cell leukemia (HCL) with chronic lymphocytic leuke

43 produce high response rates in patients with hairy cell leukemia (HCL), a significant number of patie

44 ), 7 of 7 follicular lymphoma (FL), 13 of 17 hairy cell leukemia (HCL), and 2 of 3 mantle cell lympho

45 ch as chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL), are associated with myelosupp

46 target on B-cell malignancies, particularly hairy cell leukemia (HCL), but its soluble extracellular

47 sions (CRs) in the majority of patients with hairy cell leukemia (HCL), neither the actual relapse ra

48 These included Hodgkin's disease (HD), hairy cell leukemia (HCL), non-Hodgkin's lymphoma (NHL),

49 e (BRAF V600E) is the key driver mutation in hairy cell leukemia (HCL), suggesting opportunities for

50 However, in hairy cell leukemia (HCL), these processes are particula

51 defining the BRAF-V600E driving mutation in hairy cell leukemia (HCL),provide extensive laboratory s

52 ious CDKN1B mutation in 16% of patients with hairy cell leukemia (HCL).

53 recently described as a molecular marker of hairy cell leukemia (HCL).

54 duces protracted remissions in patients with hairy cell leukemia (HCL).

55 nd also occurs in the hematopoietic neoplasm hairy cell leukemia (HCL).

56 accepted as the agent of choice in treating hairy cell leukemia (HCL).

57 tibody, rituximab, in relapsed or refractory hairy cell leukemia (HCL).

58 ates when used as first-line monotherapy for hairy cell leukemia (HCL); however, patients continue to

59 low-grade follicular lymphoma (FL; n = 44), hairy cell leukemia (HCL; n = 15), and reactive lymphoid

60 cally, this paper describes the frequency of hairy cell leukemia among all adult leukemias and charac

61 ons is helpful in the diagnosis of classical hairy cell leukemia and a number of histiocytic neoplasm

62 marker of disease activity in patients with hairy cell leukemia and adult T-cell leukemia/lymphoma.

63 Immunotoxin therapy is very effective in hairy cell leukemia and also has activity in other hemol

64 cladribine) is effective in the treatment of hairy cell leukemia and chronic lymphocytic leukemia.

65 lymphoid neoplasm subtypes, most notably for hairy cell leukemia and follicular lymphoma, black predo

66 ate of complete remissions in drug-resistant hairy cell leukemia and has a lower response rate in ped

67 RITs have shown efficacy in refractory hairy cell leukemia and in some children with acute lymp

68 with reports of only a few cases of variant hairy cell leukemia and neurological disease associated

69 ladribine is best known for the treatment of hairy cell leukemia and other lymphoid cancers, it also

70 The description of hairy cell leukemia as a specific clinical entity was pu

71 issions in most patients with drug-resistant hairy cell leukemia but had less activity in leukemias w

72 HA22 is very active in drug-resistant hairy cell leukemia but is less active in children with

73 V600E-expressing human primary melanoma and hairy cell leukemia cells.

74 The Hairy Cell Leukemia Foundation convened an international

75 ibine followed by rituximab in patients with hairy cell leukemia including the vari-ant form (HCLv).

76 Hairy cell leukemia is a chronic B-cell disorder that fo

77 Hairy cell leukemia is an indolent, chronic B-cell lymph

78 Hairy cell leukemia is an uncommon hematologic malignanc

79 Although hairy cell leukemia is uniquely sensitive to interferon-

80 N-alpha2b were approved for the treatment of hairy cell leukemia just 11 years ago.

81 Enormous progress in the treatment of hairy cell leukemia over the last five decades has emerg

82 Treatment of hairy cell leukemia should be considered for symptomatic

83 Immunophenotypic features in classic hairy cell leukemia show that the leukemic cells express

84 entostatin is a highly effective regimen for hairy cell leukemia that produces durable complete respo

85 utcome of young patients with a diagnosis of hairy cell leukemia treated with cladribine.

86 Hairy cell leukemia variant (HCLv) presents with high di

87 A total of 358 patients with hairy cell leukemia were treated with cladribine at 0.08

88 notoxin treatment and report that samples of hairy cell leukemia with high levels of Bim protein resp

89 relapse-free survival times in patients with hairy cell leukemia, a disease that historically had bee

90 ity against chronic lymphocytic leukemia and hairy cell leukemia, in general, monoclonal antibodies h

91 , an immunotoxin with impressive activity in hairy cell leukemia, is in phase II trials in CLL as wel

92 al blood samples obtained from patients with hairy cell leukemia, marginal zone lymphoma, and chronic

93 lymphoma, CLL, acute lymphoblastic leukemia, hairy cell leukemia, non-Hodgkin lymphoma (including rit

94 splenomegaly, constitutional symptoms due to hairy cell leukemia, or recurrent serious infections.

95 d many complete remissions in drug-resistant Hairy cell leukemia, where many treatment cycles can be

96 ts profound impact on the natural history of hairy cell leukemia, with responses approaching 100% and

97 Only 2 of 40 deaths were attributed to hairy cell leukemia.

98 denosine analog, is clinically effective for hairy cell leukemia.

99 y profile when administered to patients with hairy cell leukemia.

100 time the clinical and pathologic features of hairy cell leukemia.

101 1 in both leukemia and lymphoma, and BRAF in hairy cell leukemia.

102 ll known and revolutionized the treatment of hairy cell leukemia.

103 signaling important for the pathogenesis of hairy cell leukemia.

104 ted kinase (ERK) in the hairy cells (HCs) of hairy cell leukemia.

105 mphomas with villous lymphocytes (SLVLs) and hairy cell leukemia.

106 e been used to treat many diseases including hairy-cell leukemia and hepatitis B and C and have also

107 CldAdo), which is the drug of choice against hairy-cell leukemia and other neoplasms, from 2'-deoxygu

108 The hairy cells (HCs) of hairy-cell leukemia are intrinsically activated mature c

109 BRAF inhibitor vemurafenib in patients with hairy-cell leukemia that had relapsed after treatment wi

110 Hairy-cell leukemia that is resistant to treatment with

111 induce complete remissions in patients with hairy-cell leukemia that is resistant to treatment with

112 d many complete remissions in drug-resistant hairy-cell leukemia when several cycles of the agent can

113 B-Raf kinase (BRAF mutations) are present in hairy-cell leukemia, cutaneous melanoma, thyroid carcino

114 BRAF V600E is the genetic lesion underlying hairy-cell leukemia.

115 tive in patients with relapsed or refractory hairy-cell leukemia.

116 isms driving variant and IGHV4-34-expressing hairy-cell leukemias, we performed whole-exome sequencin

117 Furthermore, in the hairy cell line EH, inhibition of Ras signaling through

118 The activation of hairy cells makes them unusually sensitive to interferon

119 Hairy cells possess clonal immunoglobulin gene rearrange

120 Functional inhibition of AP-1 expressed by hairy cells reduced CD11c promoter activity by 80%.

121 Comparison of nuclear extracts prepared from hairy cells with those prepared from other cell types in